The Center for Biosimilars recaps the top 5 biosimilars articles for the week of March 12, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 12.
Number 5: The European Commission has issued its eighth report on drug patent settlements, in which it found that pay-for-delay settlements in Europe have stabilized at a low level.
Number 4: A recently published study finds that biosimilar infliximab is the most cost-effective biologic treatment for fistulizing Crohn disease.
Number 3: A study investigating drivers of high spending on healthcare in the United States found that brand-name drug prices play a key role.
Number 2: Results from the VOLTAIRE-RA study showed that switching from the reference adalimumab to Boehringer Ingelheim’s FDA-approved biosimilar did not impact efficacy, safety, or immunogenicity.
Number 1: A new report predicts that 2018 will mark the beginning of a new, large wave of biosimilars.
Finally, last week, our e-newsletter asked for your thoughts on whether patient assistance programs contribute to the problem of high drug costs. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.